Predictors of survival in patients with upper tract urothelial carcinoma after surgical treatment

Background. Upper tract urothelial carcinoma (UTUC) accounts for only 5–10 % of all urothelial cancer sites. Radical nephroureterectomy is the main treatment method in patients without distant metastases.

Aim. To study survival and assess the impact of preand postoperative clinical and pathomorphological factors on the risk of death in patients with UTUC after surgical treatment.

Materials and methods. The results of surgical treatment of 157 patients with UTUC over a ten-year period were analyzed. Radical nephroureterectomy was performed in 151 (96.1 %) patients. Organ-preserving treatment was used in 6 (5.9 %) cases. Smoking was registered in 64 (40.8 %) patients. Obesity was observed in 40 (36.4 %) of 110 (70.1 %) patients available for analysis. Overall (OS), cancer-specific (CSS), progression-free (PFS), and recurrence-free survival rates were estimated. Univariate and multivariate Cox regression analysis was used to assess the impact of clinical and pathomorphological factors on the risk of patient death.

Results. The 5-year OS, CSS, and PFS were 67.9, 76.5, and 74.2 %, respectively. The 5-year recurrence-free survival was 73.4 %. The 5-year OS in the obese group was 72.7 % versus 56.5 % in the non-obese group (p = 0.042). In obese patients, there was statistically significant predominance of women (p = 0.001), significantly lower proportion of patients with regional lymph node involvement (p = 0.041), and a significantly lower number of smoking patients (p = 0.049). According to multivariate regression analysis, the risk of death was significantly increased in patients with Charlson comorbidity index above 5 (hazard ratio (HR) 2.34; 95 % confidence interval (CI) 1.33–4.11; p <0.001) and regional lymph node involvement (HR 2.78; 95 % CI 1.36–5.70; p <0.001). Multivariate analysis showed that development of non-muscle invasive recurrence in the bladder decreased the risk of death after surgical treatment (HR 0.23; 95 % CI 0.08–0.61; p = 0.003).

Conclusion. Such factors as advancement of the primary tumor and initial somatic status of the patient have negative impact on the risk of patient death after surgical treatment of UTUC. Patients with obesity have better OS, CSS, PFS, are significantly more often female, significantly rarer have regional lymph node involvement and smoke. Development of non-muscle invasive recurrence in the bladder significantly reduces the risk of patient death.

1. Siegel R., Miller K., Fuchs H. et al. Cancer Statistics, 2021. CA Cancer J Clin 2021;71(1):7–33. DOI: 10.3322/caac.21654

2. Joshi S., Quast L., Chang S. et al. Effects of tumor size and location on survival in upper tract urothelial carcinoma after nephroureterectomy. Indian J Urol 2018;34(1):68–73. DOI: 10.4103/iju.IJU_216_17

3. Dominguez­Escrig J.L., Peyronnet B., Seisen T. et al. Potential benefit of lymph node dissection during radical nephroureterectomy for upper tract urothelial carcinoma: a systematic review by the European association of urology guidelines panel on non­ muscle­invasive bladder cancer. Eur Urol Focus 2019;5(2):224–41. DOI: 10.1016/j.euf.2017.09.015

4. Ehdaie B., Chromecki T., Lee R. et al. Obesity adversely impacts disease specific outcomes in patients with upper tract urothelial carcinoma. J Urol 2011;186(1):66–72. DOI: 10.1016/j.juro.2011.03.031

5. Rink M., Xylinas E., Margulis V. et al. Impact of smoking on oncologic outcomes of upper tract urothelial carcinoma after radical nephroureterectomy. Eur Urol 2013;63(6):1082–90. DOI: 10.1016/j.eururo.2012.06.029

6. Shigeta K., Kikuchi E., Abe T. et al. A novel risk­based approach simulating oncological surveillance after radical nephroureterectomy in patients with upper tract urothelial carcinoma. Eur Urol Oncol 2020;3(6):756–63. DOI: 10.1016/j.euo.2019.06.021

7. Lwin A., Hsu C., Chipollini J. et al. Urothelial carcinoma of the renal pelvis and ureter: does location make a difference? Clin Genitourin Cancer 2020;18(1):45–9.e1. DOI: 10.1016/j.clgc.2019.10.023

8. Brusselaers N., Lagergren J. The Charlson comorbidity index in registry­based research. Methods Inf Med 2017;56(5):401–6. DOI: 10.3414/ME17­01­0051

9. Brierley J., Gospodarowicz M., Wittekind C. TNM Classification of Malignant Tumours, 8th edition. Wiley­Blackwell, December 2016.

10. Soukup V., Capoun O., Cohen D. et al. Prognostic performance and reproducibility of the 1973 and 2004/2016 World Health Organization grading classification systems in non­muscle­invasive bladder cancer: a European Association of Urology Non­muscle Invasive Bladder Cancer Guidelines Panel systematic review. Eur Urol 2017;72(5):801–13. DOI: 10.1016/j.eururo.2017.04.015

11. Simsir A., Sarsik B., Cureklibatir I. et al. Prognostic factors for upper urinary tract urothelial carcinomas: stage, grade, and smoking status. Int Urol Nephrol 2011;43(4):1039–45. DOI: 10.1007/s11255­011­9915­z

12. Rink M., Xylinas M., Trinh Q. et al. Gender­specific effect of smoking on upper tract urothelial carcinoma outcomes. BJU Int 2013;112(5):623–37. DOI: 10.1111/bju.12014

13. Osch F., Jochems S., Schooten F. et al. Significant role of lifetime cigarette smoking in worsening bladder cancer and upper tract urothelial carcinoma prognosis: a meta­analysis. J Urol 2016; 195(4 Pt 1):872–9. DOI: 10.1016/j.juro.2015.10.139

14. Miyazaki J., Nishiyama H., Fujimoto H. et al. Impact of smoking on the age at diagnosis of upper tract urothelial carcinoma: subanalysis of the Japanese urological association multi­institutional national database. Int J Urol 2015;22(11):1023–7. DOI: 10.1111/iju.12886

15. Xylinas E., Kluth L., Rieken M. et al. Impact of smoking status and cumulative exposure on intravesical recurrence of upper tract urothelial carcinoma after radical nephroureterectomy. BJU Int 2014;114(1):56–61. DOI: 10.1111/bju.12400

16. Hagiwara M., Kikuchi E., Tanaka N. et al. Impact of smoking status on bladder tumor recurrence after radical nephroureterectomy for upper tract urothelial carcinoma. J Urol 2013;189(6):2062–8. DOI: 10.1016/j.juro.2013.01.024

17. Dabi Y., Mrini M., Duquesnes I. et al. Impact of body mass index on the oncological outcomes of patients treated with radical nephroureterectomy for upper tract urothelial carcinoma. World J Urol 2018;36(1):65–71. DOI: 10.1007/s00345­017­2095­4

18. Kim H., Jeong C., Kwak C. et al. Can body mass index predict survival outcomes in patients treated with radical nephroureterectomy for upper­tract urothelial carcinoma? Int Urol Nephrol 2015;47(8):1311–20. DOI: 10.1007/s11255­015­1039­4

19. Liu J., Li Y., Liu Z. et al. Influence of body mass index on oncological outcomes in patients with upper urinary tract urothelial carcinoma treated with radical nephroureterectomy. Int J Urol 2014;21(2):136–42. DOI: 10.1111/iju.12208

20. Yeh H., Li C., Chien T. et al. Interethnic differences in the impact of body mass index on upper tract urothelial carcinoma following radical nephroureterectomy. World J Urol 2021;39(2):491–500. DOI: 10.1007/s00345­020­03204­0

21. Орлов А.С., Магер В.О., Щеглова В.П. и др. Влияние немы­ шечно­инвазивного рецидива уротелиального рака верхних мочевых путей на выживаемость пациентов после радикаль­ ной нефруретерэктомии. Уральский медицинский журнал 2024;23(4):104–15. DOI: 10.52420/umj.23.4.104